Noura S Dosoky1, Lilu Guo1, Zhongyi Chen1, Andrew V Feigley1, Sean S Davies1. 1. Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University , Rm 556 Robinson Research Building, 2200 Pierce Avenue, Nashville, Tennessee 37232-6602, United States.
Abstract
Engineering the gut microbiota to produce specific beneficial metabolites represents an important new potential strategy for treating chronic diseases. Our previous studies with bacteria engineered to produce N-acyl-phosphatidylethanolamines (NAPEs), the immediate precursors of the lipid satiety factors N-acyl-ethanolamides (NAEs), found that colonization of these bacteria inhibited development of obesity in C57BL/6J mice fed a high fat diet. Individual NAE species differ in their bioactivities. Intriguingly, colonization by our engineered bacteria resulted in increased hepatic N-stearoyl-ethanolamide (C18:0NAE) levels despite the apparent inability of these bacteria to biosynthesize its precursor N-stearoyl-phosphatidylethanolamine (C18:0NAPE) in vitro. We therefore sought to identify the factors that allowed C18:0NAPE biosynthesis by the engineered bacteria after colonization of the intestinal tract. We found that the species of NAPE biosynthesized by engineered bacteria depends on the species of dietary fatty acids available in the intestine, suggesting a simple method to fine-tune the therapeutic effects of modified microbiota.
Engineering the gut microbiota to produce specific beneficial metabolites represents an important new potential strategy for treating n class="Disease">chronic diseases. Our previous studies with bacteria engineered to produce N-acyl-phosphatidylethanolamines (NAPEs), the immediate precursors of the lipid satiety factors N-acyl-ethanolamides (NAEs), found that colonization of these bacteria inhibited development of obesity in C57BL/6J mice fed a high fat diet. Individual NAE species differ in their bioactivities. Intriguingly, colonization by our engineered bacteria resulted in increased hepatic N-stearoyl-ethanolamide (C18:0NAE) levels despite the apparent inability of these bacteria to biosynthesize its precursor N-stearoyl-phosphatidylethanolamine (C18:0NAPE) in vitro. We therefore sought to identify the factors that allowed C18:0NAPE biosynthesis by the engineered bacteria after colonization of the intestinal tract. We found that the species of NAPE biosynthesized by engineered bacteria depends on the species of dietary fatty acids available in the intestine, suggesting a simple method to fine-tune the therapeutic effects of modified microbiota.
Entities:
Keywords:
N-acyl-ethanolamides; N-acyl-phosphatidylethanolamines; N-acyltransferases; engineered bacteria; fatty acids; gut microbiota
Authors: Jin Fu; Giuseppe Astarita; Silvana Gaetani; Janet Kim; Benjamin F Cravatt; Ken Mackie; Daniele Piomelli Journal: J Biol Chem Date: 2006-11-22 Impact factor: 5.157
Authors: M Dalle Carbonare; E Del Giudice; A Stecca; D Colavito; M Fabris; A D'Arrigo; D Bernardini; M Dam; A Leon Journal: J Neuroendocrinol Date: 2008-05 Impact factor: 3.627
Authors: Matthew P Gillum; Dongyan Zhang; Xian-Man Zhang; Derek M Erion; Rachel A Jamison; Cheolsoo Choi; Jianying Dong; Marya Shanabrough; Hillary R Duenas; David W Frederick; Jennifer J Hsiao; Tamas L Horvath; Chun Min Lo; Pat Tso; Gary W Cline; Gerald I Shulman Journal: Cell Date: 2008-11-28 Impact factor: 41.582
Authors: Noura S Dosoky; Zhongyi Chen; Yan Guo; Clara McMillan; C Robb Flynn; Sean S Davies Journal: Appl Microbiol Biotechnol Date: 2019-06-15 Impact factor: 4.813
Authors: Silvia Tagliamonte; Chris I R Gill; L Kirsty Pourshahidi; Mary M Slevin; Ruth K Price; Rosalia Ferracane; Roger Lawther; Gloria O'Connor; Paola Vitaglione Journal: Eur J Nutr Date: 2020-10-26 Impact factor: 5.614